1. Ries LAG, Melbert D, Krapcho M et al. SEER cancer statistics review, 1975–2004. Bethesda: National Cancer Institute, 2004.
2. Sklar CA. Childhood brain tumors. J Pediatr Endocrinol Metab 2002; 15 (Suppl. 2): 669–73.
3. Gurney JG, Kadan-Lottick NS, Packer RJ et al. Endocrine and cardiovascular late effects among adult survivors of childhood brain tumors. Cancer 2003; 97 (3): 663–73.
4. Littley MD, Shalet SM, Beardwell CG et al. Radiation induced hypopituitarism is dose dependent. Clin Endocrinol (Oxf) 1989; 31: 363–73.
5. Ahmed SR, Shalet SM. Hypothalamic growth hormone releasing factor deficiency following cranial irradiation. Clin Endocrinol 1984; 21: 483–8.
6. Samaan R, Vieto R, Schultz PN et al. Hypothalamic pituitary dysfunction after radiotherapy to the head and neck. Int J Radiat Oncol Biol Phys 1982; 8: 1857–67.
7. Sklar CA, Constine LS. Chronic neuroendocrine sequelae of radiation therapy. Int J Rad Oncol Biol Phys 1995; 31: 1113–21.
8. Spoudeas HA, Hindmarsh PC, Matthews DR et al. Evolution of growth hormone neurosecretory disturbance after cranial irradiation for childhood brain tumours: a prospective study. J Endocrinol 1996; 150 (2): 329–42.
9. Gleeson HK, Shalet SM. The impact of cancer therapy on the endocrine system in survivors of childhood brain tumours. Endocrine-Related Cancer 2004; 11: 589–602.
10. Albertsson-Wikland K, Lannering B, Marky I et al. A longitudinal study on growth and spontaneous growth hormone (GH) secretion in children with irradiated brain tumors. Acta Pediatr Scand 1987; 76 (6): 966–73.
11. Clayton PE, Shalet SM. Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 1991; 11: 226–8.
12. Voorhess ML, Brecher ML, Glickman AS et al. Hypothalamic-pituitary function of children with acute lymphoblastic leukemia after three forms of central nervous system prophylaxis. Cancer 1986; 57: 1287–91.
13. Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J Clin Endocrinol Metab 199; 78: 1282–87.
14. Lannering B, Jansson C, Rosberg S et al. Increased LH and FSH secretion after cranial irradiation in boys. Med Pediatr Oncol 1997; 29: 280–7.
15. Constine LS, Woolf PD, Cann D et al. Hypothalamic-pituitary dysfunction after radiation for brain tumors. N Engl J Med 1993; 328: 87–94.
16. Crowne EC, Wallace WHB, Gibson S et al. Adrenocorticotropin and cortisol secretion in children after low dose cranial irradiation. Clin Endocrinol 1993; 39: 59–68.
17. Schmiegelow M, Feldt-Rasmussen U, Lange M et al. Assessment of hypothalamic-pituitary-adrenal axis in patients treated with radiotherapy and chemotherapy for childhood brain tumour. J Clin Endocrinol Metab 2003; 88: 3149–54.
18. Rose SR, Danish RK, Kearney NS et al. ACTH deficiency in childhood cancer survivors. Pediatr Blood Cancer 2005; 45: 808–13.
19. Littley MD, Shalet SM, Beardwell CG et al. Radiation and hypothalamic-pituitary function. Baillieres Clin Endocrinol Metab 1990; 4: 147–75.
20. Schmiegelow M, Feldt-Rasmussen U, Rasmussen AK et al. A population-based study of thyroid function after radiotherapy and chemotherapy for a childhood brain tumor. J Clin Endocrinol Metab 2003; 88 (1): 136–40.
21. Rose SR, Lustig RH, Pitukcheewanont P et al. Diagnosis of hidden central hypothyroidism in survivors of childhood cancer. J Clin Endocrinol Metab 1999; 84: 4472–79.
22. Schmiegelow M, Lassen S, Poulsen HS et al. Gonadal status in male survivors following childhood brain tumors. J Clin Endocrinol Metab 2001; 86: 2446–52.
23. Petersen PM, Andersson AM, Rorth M et al. Undetectable inhibin B levels in men after testicular irradiation. J Clin Endocrinol Metab 1999; 84: 213–5.
24. Clayton PE, Shalet SM, Price DA. Ovarian function following chemotherapy for childhood brain tumours. Med Pediatr Oncol 1989; 17: 92–6.
25. Joint Council for Clinical O: Management of gonadal toxicity resulting form the treatment of adult cancer. Royal College of Physicians. In., 1998.
26. Sigurdson AJ, Ronckers CM, Mertens AC. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. 2005; 365: 2014–23.
27. Gurney JG, Ness KK, Stovall M et al. Final height and body mass index among adult survivors of childhood brain cancer: Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2003; 88 (10): 4731–39.
28. Shalet SM, Gibson B, Swindell R et al. Effects of spinal irradiation on growth. Arch Dis Child 1987; 62: 461–4.
29. Ogilvy-Stuart AL, Shalet SM. Growth and puberty after growth hormone treatment after irradiation for brain tumours. Arch Dis Child 1995; 73: 141.
30. Lustig RH, Post SR, Srivannaboon K et al. Risk factors for the development of obesity in children surviving brain tumors. J Clin Endocrinol Metab 2003; 88: 611–6.
31. Duffner PK. Long-term effects of radiation therapy on cognitive and endocrine function in children with leukemia and brain tumors. Neurologist 2004; 10 (6): 293–310.
32. Gleeson HK, Stoeter R, Ogilvy-Stuart AL et al. Improvements in final height over 25 years in growth hormone (GH)-deficient childhood survivors of brain tumors receiving GH replacement. J Clin Endocrinol Metab 2003; 88 (8): 3682–9.
33. Packer RJ, Boyett JM, Janss AJ et al. Growth hormone replacement therapy in children with medulloblastoma: Use and effect on tumor control. 
J Clin Oncol 2001; 19: 480–7.
34. Sklar CA, Mertens AC, Mitby P et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2002; 87 (7): 3136–41.
35. Xu W, Janss A, Moshang T. Adult height and adult sitting height in childhood medulloblastoma survivors. J Clin Endocrinol Metab 2003; 88 (10): 4677–81.
36. Cohen P, Clemmons DR, Rosenfeld RG. Does the GH-IGF axis play a role in cancer pathogenesis. Growth Horm IGF Res 2000; 10: 297–305.
38. Ranke MB, Price DA, Lindberg A et al. Final height in children with medulloblastoma treated with growth hormone. Hormone Research 2005; 64: 28–34.
38. Adan I, Sainte-Rose C, Souberbielle JC et al. Adult height after growth hormone (GH) treatment for growth hormone deficiency due to cranial irradiation. Med Pediatr Oncol 2000; 34: 14–19.
39. Abir R, Fisch B, Raz A et al. Preservation of fertility in women undergoing chemotherapy: current approach and future prospects. Assist Reprod Genet 1998; 15: 469–77.
40. Meirow D, Levron J, Eldar-Geva T et al. Monitoring the ovaries after autotransplantation of cryopreserved ovarian tissue: endocrine studies, in vitro fertilization cycles, and live birth. Fertil steril 2007; 87 (2): 418e417–418e415.
41. Stewart PM, Corrie J, Seckl JR et al. A rational approach for assessing the hypothalamo-pituitary-adrenal axis. Lancet 1988; 1: 1208–10.
42. Orme SM, Peacey SR, Barth JH, Belchetz PE. Comparison of tests of stress-released cortisol secretion in pituitary disease. Clin Endocrinol (Oxf) 1996; 45 (2): 135–40.
43. Toogood AA. Endocrine consequences of brain irradiation. Growth Horm IGF Res 2004; 14 (Suppl. A): 118–24.
44. Barnes ND. Effects of external irradiation on the thyroid gland in childhood. Horm Res 1988; 30: 84–9.
45. Xu W, Janss A, Packer RJ et al. Endocrine outcome in children with medulloblastoma treated 18 Gy of craniospinal radiation therapy. Neuro-Oncol 2004; 6: 113–8.
46. Carrie C, Hoffstetter S, Gomez F et al. Impact of targeting deviations on outcome in medulloblastoma: study of the French Society of Pediatric Oncology (SFOP). Int J Radiat Oncol Biol Phys 1999; 45: 435–9.
47. Ricardi U, Corrias A, Einaudi S et al. Thyroid dysfunction as a late effect in childhood medulloblastoma: a comparison of hyperfractionated versus conventional fractionated craniospinal radiotherapy. Int J Radiat Oncol Biol Phys 2001; 50: 1287–94.
48. Blumenfeld Z, Haim N. Prevention of gonadal damage during cytotoxic therapy. Ann Med 1997; 29:199–206.

Н.А.Мазеркина 

НИИ нейрохирургии им. академика Н.Н.Бурденко РАМН, Москва